Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers
Yuting Sun, Xuelei Chu, Xinmiao Wang, Weina Li, Xiaoyu Zhu, Guanghui Zhu, Xinyi Ma, Xue He, Jie Li · 2026
Read Guiding the Application of Immunotherapy in Nonsmall Cell Lung Cancer: The Role of Biomarkers by Yuting Sun, Xuelei Chu, Xinmiao Wang, Weina Li, Xiaoyu Zhu, Guanghui Zhu, Xinyi Ma, Xue He, Jie Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13601740.txt.
Description
Yuting Sun and eight co-authors review how biomarkers can steer immunotherapy for the most common form of lung cancer. Drugs that release the immune system against nonsmall cell lung cancer have changed care, but responses vary wildly, resistance develops, and immune side effects are hard to manage. Picking the right patients needs better signals than the single PD-L1 stain used today.
The review maps a widening radar: features of the tumor's microenvironment, its genetic profile, body-wide inflammation and immune measures, and imaging-based radiomics all add predictive power. It also lists how suppressive surroundings and particular mutations drive resistance, and which clinical and blood markers flag risk of immune-related harm. The authors look ahead to dynamic models that fuse multi-layer gene data, repeated liquid biopsies, and AI into a live decision system for real-time monitoring.
Catalog record
| CREATOR | Yuting Sun, Xuelei Chu, Xinmiao Wang, Weina Li, Xiaoyu Zhu, Guanghui Zhu, Xinyi Ma, Xue He, Jie Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |